HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tovey, M. G. Articles by Rochette-Egly, C. Search for Related Content PubMed Articles by Tovey, M. G. Articles by Rochette-Egly, C.

The Effect of Mitogens on the Expression of Epstein-Barr Virus Antigens in Human Lymphoid Cell Lines¹

From the Institut de Recherches Scientifiques sur le Cancer, Villejuif, the International Agency for Research on Cancer, Lyon, the Institut de Cancérologie et d'Immunogénétique, Villejuif, and the Institut de Chimie Biologique, Faculté de Médecine, Strasbourg, France

Abstract

Treatment of human lymphoblastoid cells with either phytohemagglutinin (PHA), concanavalin A, Staphylococcus protein A, or polyinosinic acid-polycytidylic acid, in combination with 5-iodo-2' deoxyuridine (IUdR) markedly increased the expression of Epstein-Barr virus (EBV) early antigen (EA) relative to IUdR alone. Such treatment did not, however, modify the production of virus capsid antigen in any of the lymphoid cell lines tested. The effect of PHA on EA induction in Raji cells was not accompanied by changes in the incorporation of labeled precursors into cellular DNA, or in the intracellular concentration of either adenosine 3'5' cyclic monophosphate or guanosine 3'5' cyclic monophosphate. However, those mitogens that stimulated EA expression in Raji cells also increased the fluorescence polarization of 1,6 diphenyl 1,3,5-hexatriene-labeled Raji cells. The possible role of cell surface changes in the mitogen activation of latent EBV in human lymphoblastoid cells is discussed.

Footnotes

¹ This work was supported in part by grants from D.R.E.T. (78-34-210), I.N.S.E.R.M. (CRL 77-4-072-1 and ATP 47-77-79), and the National Cancer Institute (Contract 1-CP-43296).